目的 建立非奈利酮藥物利用評價（DUE）標(biāo)準(zhǔn)，為臨床合理應(yīng)用非奈利酮提供參考。方法 參考非奈利酮的說明書、相關(guān)指南、專家共識等，運(yùn)用專家咨詢法，從用藥指征、用藥過程、用藥結(jié)果3個方面建立非奈利酮的DUE標(biāo)準(zhǔn)。回顧性研究福建醫(yī)科大學(xué)附屬南平第一醫(yī)院2023年4月—2024年12月使用非奈利酮的病歷，進(jìn)行合理用藥評價。結(jié)果 建立的非奈利酮DUE標(biāo)準(zhǔn)含3級指標(biāo)，包括一級指標(biāo)3項，二級指標(biāo)10項，三級指標(biāo)26項。共納入使用非奈利酮的病例406例，合理325例，合理率為80.05%，不合理情況主要為適應(yīng)證不適宜（4.93%）、起始劑量不適宜（19.70%）和藥物相互作用（5.17%）等方面。結(jié)論 建立的非奈利酮DUE標(biāo)準(zhǔn)具有較強(qiáng)的科學(xué)性、實用性和可行性，可為臨床合理用藥提供參考依據(jù)。

Objective To establish the drugusee valuation (DUE) standard of finerenone, and to provide reference for the rational clinical application of finerenone. Methods Based on the ticagrelor drug label, related guidelines and literature, combined with clinical expert consulation results, DUE standard from three levels (indications, medications, and medication results) was estiblished. The medical records of fenelidone in Nanping First Hospital of Fujian Province from April 2023 to December 2024 were retrospectively studied to evaluate rational drug use. Results The DUE of finerenone included 3 primary indexes, 10 secondary indexes, and 26 tertiary indexes. A total of 406 cases of using finerenone were included, of which the rational rate was 80.05%. The irrational cases were mainly off-label use (4.93%), unreasonable initial dose (19.70%), and drug interaction (5.17%). Conclusion The established DUE standard of finerenone is scientific, practical, and feasible, which can provide reference for clinical rational drug use.

R972

福建省自然科學(xué)基金資助項目（2022J011488）